Crestline Management, L.P. (“Crestline”) is excited to announce the close of a new first lien credit facility to Vetnique Labs, LLC ("Vetnique"). Crestline served as agent for the transaction. Vetnique, a portfolio company of Gryphon, is a veterinarian-founded, veterinarian-formulated, veterinarian-recommended pet health and wellness company focused on science-based pet supplements.
"Vetnique has established itself as a leading brand in pet health and wellness, delivering consumer-trusted and vet-recommended solutions in digestive and mobility care," said Josh Witczak, Vice President at Crestline. “Crestline is excited to partner with a leading pet health and wellness company and deepen our relationship with Gryphon Investors,” added Henry Wang, Managing Director at Crestline.
About Crestline Management, L.P.
Crestline is a global alternative investment management firm founded in 1997 and based in Fort Worth, Texas, with affiliate offices in London, New York, Tokyo, and Toronto. The firm has approximately $17.5 billion of credit assets under management (as of December 31, 2025) including its capital solutions, direct lending, and portfolio finance platforms. For more information, visit www.crestlineinvestors.com.
About Gryphon Investors
Gryphon Investors is a leading middle-market private investment firm focused on profitably growing competitively advantaged companies in the Business Services, Consumer, Healthcare, Industrial Growth, Software, and Technology Solutions & Services sectors. With approximately $10 billion of assets under management, Gryphon prioritizes investments in which it can form strong partnerships with founders, owners, and executives to accelerate the building of leading
companies and generate enduring value through its integrated deal and operations business model. Gryphon’s highly differentiated model integrates its well-proven Operations Resources Group, which is led by full-time, Gryphon senior operating executives with general management, human capital acquisition and development, treasury, finance, and accounting expertise. Gryphon’s three core investment strategies include its Flagship, Heritage, and Junior Capital strategies, each with dedicated funds of capital. The Flagship and Heritage strategies target equity investments of $50 million to $500 million per portfolio company. The Junior Capital strategy targets investments of $10 million to $25 million in junior securities of credit facilities, arranged by leading middle-market lenders, in both Gryphon-controlled companies, as well as in other private equity-backed companies operating in Gryphon’s targeted investment sectors. For more information, visit www.gryphoninvestors.com/.
About Vetnique
Vetnique is a global pet wellness company dedicated to helping pets thrive through scientifically backed, vet formulated solutions. One of the world’s fastest-growing omnichannel pet health organizations, Vetnique is recommended by more than 125,000 veterinarians worldwide, trusted by millions of pet parents, and has earned over 200,000 five-star reviews globally. Each year, Vetnique supports the health and well-being of more than 5 million pets around the world.
Built on a foundation of veterinary expertise, scientific rigor, and premium ingredients, Vetnique brings the same high standard of care across its entire portfolio, including its two leading product lines: Glandex®, the company’s flagship digestive health solution, and YuMOVE®, a clinically supported joint health supplement. Guided by real-world veterinary insight and a commitment to meaningful innovation, Vetnique develops solutions that deliver real results for pets and the people who care for them. Learn more at Vetnique.com.
Uniquely Vet Founded. Vet Formulated. Vet Recommended.
This financial promotion is issued by Crestline Management, LP and Crestline Europe, LLP (together "Crestline"). Crestline Europe, LLP is authorized and regulated by the Financial Conduct Authority (FCA). The material is not intended to be a formal research report and nothing in this presentation should be interpreted to state or imply that past results are an indication of future performance. Any opinions expressed herein are our current opinions only. There can be no assurance or guarantee that Crestline's investment strategy will achieve its stated goal. All information provided in this presentation is for informational purposes only Crestline accepts no liability for loss arising from the use of this material. In the United Kingdom, this communication is being made only to, or directed only at, persons who are: (i) investment professionals within the meaning of Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“FP Order”); (ii) high net worth companies and certain other entities falling within Article 49 of the FP Order; or (iii) any other persons to whom such communication may lawfully be made. It must not be acted, or relied, upon by any other persons.
